radio-labeled naquotinib + naquotinib
Phase 1Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epidermal Growth Factor Receptor (EGFR) Mutations
Conditions
Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors
Trial Timeline
Nov 15, 2016 → Nov 15, 2016
NCT ID
NCT02674555About radio-labeled naquotinib + naquotinib
radio-labeled naquotinib + naquotinib is a phase 1 stage product being developed by Astellas Pharma for Epidermal Growth Factor Receptor (EGFR) Mutations. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02674555. Target conditions include Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors.
What happened to similar drugs?
1 of 4 similar drugs in Epidermal Growth Factor Receptor (EGFR) Mutations were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02674555 | Phase 1 | Withdrawn |
Competing Products
13 competing products in Epidermal Growth Factor Receptor (EGFR) Mutations
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 26 |
| Erlotinib | Astellas Pharma | Phase 2 | 27 |
| KRN23 | Kyowa Kirin | Phase 2 | 35 |
| SHR6390 + placebo | Jiangsu Hengrui Medicine | Phase 3 | 44 |
| ABT-414 | AbbVie | Pre-clinical | 26 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 40 |
| Venetoclax + Fulvestrant | Roche | Phase 2 | 27 |
| Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine | Roche | Phase 3 | 40 |
| Palbociclib + Everolimus + Exemestane | Pfizer | Phase 1/2 | 32 |
| Palifermin | Swedish Orphan Biovitrum | Phase 1/2 | 24 |
| Crysvita (burosumab-twza) Treatment | Ultragenyx Pharmaceutical | Approved | 37 |
| FDX104 (4% Doxycycline) | Vyne Therapeutics | Phase 2 | 25 |
| ATR-04 | Azitra | Phase 1/2 | 14 |